Express Scripts Claims New Hepatitis C Therapy will Cost Illinois $2.3B

wpid-Photo-20140711095706.jpg

According to a report that Express Scripts released state legislatures will need to find billions in their budgets to purchase costly new hepatitis C therapy, according to a new state-by-state analysis released today by Express Scripts (NASDAQ: ESRX). But their report is near sighted only looking at the immediate costs of the prescription, instead of the longterm cost stagings this therapy can provide.

Continue reading

White House asks Congress to Stop Tax Inversion Deals

Originally posted on Pharmalot

Crowdfuning-Bank

All those drug makers and investment banks chasing tax inversions now face opposition from the Obama administration. Yesterday, U.S. Treasury Secretary Jacob Lew wrote the House Ways & Means Committee, which composes tax law, to urge immediate legislation that would “shut down this abuse of our tax system.” And he suggests making any law retroactive to May 2014.

Continue reading

President’s advisory group calls for clinical trial changes, incentives for antibiotics R&D

wpid-Photo-20140711095706.jpg

With antibiotic resistance on the rise at a time when Big Pharma has largely vacated the risk-heavy field, the President’s Council of Advisors on Science and Technology (PCAST) is proposing a number of recommendations to lure companies back into the arena and help speed up the development of new antibiotics.

Continue reading

Speciality Tiers Restrict Access to New Medicines and can Endanger Lives

access.restricted

Next Friday I will be hosting a roundtable discussion with the Arthritis Foundation, the American Liver Foundation; and the Leukemia and Lymphoma Society on the importance of innovation and patient access to new medicines. It is a free event and I would encourage you to attend. Also there will be an iBIO BBQ immediately following the event. 

Continue reading

Patent law is good for big pharma because it has no innovators

 

PrescriptionAssistanceMast

A new study adds some empirical firepower to the idea that poor patent laws are crushing innovation in the technology industry. Researchers from the London School of Economics studied citations from patents that were invalidated by U.S. judges and found that invalidation increased the number of subsequent innovations in technology, but not in pharmaceuticals.

Continue reading